Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 51 clinical trials
Pan-Canadian Lung Cancer Observational Study (PALEOS)

This study is a multicenter, ambispective observational study that will collect data focusing on patients with lung cancers in Canada. The study will begin with ALK, EGFR, ROS1, ERBB2 (HER2

lung cancer
cancer
lung carcinoma
HER2
EGFR
  • 1 views
  • 14 Jul, 2022
  • 1 location
CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS) (CARMA-BROS)

that help to stop the cancer. These rare changes occur in genes such as but not limited to ALK, EGFR, ROS1, and BRAF, which have targeted drugs in a family known as tyrosine kinase inhibitors (TKIs

KRAS
cancer diagnosis
BRAF
cancer care
ROS1
  • 1 views
  • 16 Jun, 2022
  • 4 locations
Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING)

This registry will make it possible to describe real life management of patients with rare actionable fusions and to better understand these cancers. In addition of clinical data from the medical files, a quality of life questionnaire (QLQ-C30) will be complete at inclusion, at each new treatment and then every …

primary cancer
  • 0 views
  • 12 Aug, 2021
  • 41 locations
Multicenter Observational Study of Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Rare Driver Gene Mutation

Title: Multicenter observational study for clinicopathological characteristics and clinical efficacy of Chinese Non-Small Cell Lung Cancer (NSCLC) patients With Rare Driver Gene Mutation. Purpose: To observe the status of rare driver gene mutations in NSCLC patients and identify the subtypes of the mutations. By comparing and analyzing the relationship between …

lung carcinoma
KIT
  • 2 views
  • 23 Jan, 2021
  • 1 location
Safety and Efficacy of Xalkori ROS1

The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug.

proto-oncogene tyrosine-protein kinase ros
recurrent non-small cell lung cancer
crizotinib
ROS1
  • 15 views
  • 07 Oct, 2022
  • 1 location
Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy

A comparison of baseline tumor characteristics in oncogene-driven cancers to tumor characteristics after early response to Tyrosine Kinase Inhibitor (TKI) targeted treatment will allow identification of early adaptive mechanisms of cell survival. This will facilitate targeting and termination of these survival/ resistance pathways before they develop with rational combinations of …

gefitinib
metastasis
erlotinib
afatinib
kinase inhibitor
  • 28 views
  • 23 Feb, 2022
  • 1 location
Real World Study on First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous Non-small Cell Lung Cancer

This study was designed to explore the efficacy and safety of Crizotinib as a first-line treatment for advanced NSCLC with ROS1 rearrangement positive mutation in the real world, explore the new

squamous non-small cell lung cancer
non-squamous non-small cell lung cancer
Accepts healthy volunteers
proto-oncogene tyrosine-protein kinase ros
lung carcinoma
  • 3 views
  • 16 Mar, 2022
  • 1 location
Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients

To evaluate the predictive value of ctDNA in response, relapse for patients treated with immune checkpoint inhibitors or targeted therapy for ALK, ROS1, MET ex14 skipping.

adenocarcinoma
squamous cell carcinoma
lung cancer
metastasis
lung carcinoma
  • 47 views
  • 27 Jan, 2021
  • 1 location
Prediction of Response to Treatment With Immunotherapy + Chemotherapy in Non-Small Cell Lung Cancer

treatment with pembrolizumab+first line chemotherapy in metastatic non-small cell lung cancer, regardless of the PD-L1 status and in the absence of ALK, ROS1 or EGFR alteration.

  • 0 views
  • 13 Apr, 2021
  • 4 locations
Study of CT and MR in the Lung Cancer

), ROS1(c-ros oncogene 1 receptor,ROS1), BRAF (V-raf murine sarcoma viral oncogene homolog B1, BRAF)and so on have clearly targeted drugs, which bring survival benefits to patients. However, about half

lung cancer
cancer
ct scan
EGFR
epidermal growth factor receptor
  • 0 views
  • 03 Mar, 2022
  • 1 location